Technetium (99mTc) nofetumomab merpentan

Technetium (^99mTc) nofetumomab merpentan (trade name Verluma) is a mouse monoclonal antibody derivative used in the diagnosis of lung cancer,^[1] gastrointestinal, breast, ovary, pancreas, kidney, cervix, and bladder carcinoma.^[2] The antibody part, nofetumomab, is attached to the chelator merpentan, which links it to the radioisotope technetium-99m (^99mTc).^[3]

Nofetumomab

Nofetumomab is an antibody fragment that recognises the pancarcinoma glycoprotein antigen EpCAM.^[4] and/or CD20/MS4A1^[5]

It is the Fab part of murine MAb NR-LU-10.^[6]

The chelator part : merpentan is a phenthioate ligand, 2,3,5,6-tetrafluorophenyl-4,5-bis-5-[1-ethoxyethyl]-thioacetoamidopentanoate.^[6]

Phenthioate is an insecticide (Cidial) = O,o-dimethyl-S-(carbethoxy-phenylmethyl)dithiophosphate^[7]

^ Straka MR, Joyce JM, Myers DT (January 2000). "Tc-99m nofetumomab merpentan complements an equivocal bone scan for detecting skeletal metastatic disease from lung cancer". Clinical Nuclear Medicine. 25 (1): 54–5. doi:10.1097/00003072-200001000-00013. PMID 10634533.
^ Breitz HB, Tyler A, Bjorn MJ, Lesley T, Weiden PL (September 1997). "Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy". Clinical Nuclear Medicine. 22 (9): 615–20. doi:10.1097/00003072-199709000-00007. PMID 9298295.
^ "International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). Geneva: World Health Organization. 2002. Archived from the original (PDF) on July 3, 2011.
^ Tsurushita N, Vasquez M (January 2004). "Humanization of monoclonal antibodies". In Reth M, Radbruch A, Alt F, Honjo T, Neuberger M (eds.). Molecular Biology of B Cells. Academic Press. pp. 533–545. ISBN 978-0-08-047950-7.
^ "Anti-MS4A1 Therapeutic Antibody (Technetium (99MTC) Nofetumomab Merpentan)". Creative BioLabs.
^ ^a ^b Mudd E (27 February 2015). "Monoclonal Antibody Radionuclide Test Kits". Pharmacological Sciences.
^ US 3934010, Drabek J, Varsanyi D, "Insecticidal composition and method utilizing phosphoric acid phenylsulphonamide esters", issued 20 January 1976, assigned to Ciba Geigy Corporation